Company

Bank

Analyst

Coverage

Opinion

Wk chg

1/17 cls

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Leerink Partners

Marko Kozul

Price target

Outperform

32%

$87.36

Kozul raised his target to $125 from $82 after Alnylam expanded its partnership with the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to develop and commercialize treatments for rare genetic diseases (see Cover Story). Kozul said the deal de-risks Alnylam's pipeline and leverages Genzyme's "proven ability" to cultivate nascent lysosomal storage disease markets. Additionally, Alnylam said last week it will acquire the Sirna Therapeutics Inc. subsidiary of Merck & Co. Inc. (NYSE:MRK). Kozul said Sirna's IP and delivery capabilities could accelerate development of Alnylam's extra-hepatic short interfering RNA (siRNA) delivery programs.